Post

AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD’s Lynparza (olaparib), with standard therapies …

Pneumagen raises £8 million for further study of intranasal antiviral

Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies …

InDex Pharmaceuticals signs licence deal with Viatris for cobitolimod

InDex Pharmaceuticals has entered a licence deal with Viatris Pharmaceutical Japan for the development and commercialisation of cobitolimod in Japan …

Algernon announces acceptance of Repirinast patent application in Japan

Algernon Pharmaceuticals’ patent application for NP-251 (Repirinast) has been accepted by the Japanese Patent Office (JPO) for the treatment of …

Negative FDA AdCom vote for Intercept’s obeticholic acid in NASH

On 19 May, the FDA’s Gastrointestinal Drugs Advisory Committee (GDAC), by a vote of 12 to two, with two abstentions, …